Kevin T. Conroy Chairman and Chief Executive Officer
Kevin T. Conroy was named President and Chief Executive Officer of Exact Sciences in April 2009. He also serves as a Director. In December 2005, he was appointed President and Chief Executive of Third Wave, and served in that position until the company's acquisition by Hologic in July 2008. He joined Third Wave in July 2004 and served as the company's general counsel until December 2005. Prior to joining Third Wave, Conroy served as Intellectual Property counsel at GE Healthcare. Before joining GE Healthcare, Conroy was Chief Operating Officer of two early stage, venture-backed technology companies in Northern California. Prior to those positions, he was an Intellectual Property litigator at two Chicago law firms: McDermott Will & Emery; and Pattishall, McAuliffe, Newbury, Hilliard and Geraldson, where he was a partner. He earned a Bachelor of Science degree in electrical engineering from Michigan State University, as well as a law degree from the University of Michigan Law School.
David A. Thompson has served as Lead Independent Director since March 2014 and as Director since July 2010. Thompson retired from Abbott Laboratories in 1995, where he served for more than 30 years in a variety of corporate officer positions including corporate senior vice president and president of Abbott Laboratories Diagnostic Division. Thompson was previously chairman and lead independent director of Third Wave Technologies Inc. and lead director of St. Jude Medical Inc. Thompson received his B.S. from South Dakota State University.
Thomas D. Carey, age 51, has served as a director since April 2013. Mr. Carey has been a member at Spencer Stuart, a global executive search firm, since 2010, where he is responsible for leading the firm's global efforts in providing board services to companies within all segments of the healthcare market. Prior to Spencer Stuart, Mr. Carey was with Russell Reynolds Associates from 2001 to 2010 where he served as a Partner and Co-Head of the firm's Global Life Sciences Practice for the three years preceding his move to Spencer Stuart. Prior to entering the search industry, Mr. Carey served as an investment banker and then chief financial officer of both private and public healthcare and information technology companies. Mr. Carey earned a bachelor's degree from the College of the Holy Cross and an MM degree in management policy from the Kellogg Graduate School of Management at Northwestern University.
Mr. Carey brings to the Board more than 20 years of broad life sciences industry expertise. His background in the executive search industry also provides the Board of Directors a valuable perspective with respect to key executive hires and other personnel-related matters.
Sally W. Crawford has served as a Director since August 1999 and served as Chairperson of the Board from January 2006 to April 2008. Crawford has been an independent healthcare consultant since January 1997. From April 1985 to January 1997, Crawford served as Chief Operating Officer for Healthsource, Inc., a managed care organization that she co-founded. Crawford is also a director of CombinatoRx, Inc., Hologic, Inc. and Universal American Corp. Crawford holds a Bachelor of Arts in English from Smith College and a Master of Science in Communication from Boston University.
Daniel J. Levangie has been a Director since July 2010. Levangie is currently President, Chief Executive Officer and a director of Keystone Dental. Prior to that, he was Managing Partner of Constitution Medical Investors, Inc. Levagie also served as President, Surgical Products Division, and as Executive Vice President and member of the Board of Directors of Cytyc Corporation from July 2006 through October 2007, when Cytyc Corporation was acquired by Hologic, Inc. He is also currently a director of Dune Medical Devices, ev3, Inc., and HyperMed, Inc.
Katherine Napier has been a Director since April 2009. She is a twenty-year veteran of Procter & Gamble, where from 1979 to 2002, she rose from Assistant Brand Manager to Vice President and General Manager of the company's North American pharmaceutical business. That business experienced unprecedented growth during her five-year tenure, which included the launch of the osteoporosis drug Actonel. Actonel grew to $1 billion in revenue more quickly than any of the company's other brands. Napier also served as Senior Vice President of Marketing at McDonald's Corp., where she led the company's reinvigoration of its business with women and families. She received her Bachelor's degree in economics and studio fine arts from Georgetown University, and earned an MBA in marketing and finance from Xavier University. Napier serves on the Board of Directors of the Alberto Culver Co., Catholic Health Care Partners, Xavier University, and the Board of Visitors of Wake Forest University Calloway School of Business. She was a Director of Mentor Corp. before its acquisition earlier this year by Johnson & Johnson, and of Third Wave Technologies Inc. until its acquisition by Hologic Inc. in 2008.
Lionel N. Sterling has served as a Director since July 2010. Sterling is president of Equity Resources, Inc., a private investment firm. He previously co-founded and served as managing partner of the private investment firm Whitehead/Sterling. He also has served as chairman of the board of directors of Rayovac Corporation, Executive Vice President and Director of United Brands Company, and Sector Executive and Chief Financial Officer of American Can Company. He has been a director of I-Stat Corporation, Third Wave technologies, and Molecular Insight Corporation. He also held various investment and operating positions at ITT Corporation and Donaldson, Lufkin & Jenrette Inc. Sterling holds an M.B.A. from New York University.
For investigational use only. The performance characteristics of this product have not been established. Certain statements contained in this website, other than historical information, consist of forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and are subject to a variety of risks and uncertainties that could cause actual results to differ materially from the results contemplated thereby. Any forward-looking statements we make should be considered in light of the risks and uncertainties described in our filings with the Securities and Exchange Commission, including but not limited to those described in our most recent Form 10-K and subsequent Forms 10-Q. We undertake no obligation to update or revise the information provided herein, whether as the result of new information, future events or circumstances or otherwise.